{"release":"wpf-flagship-weight-management","version":"1.0.0","archived":true,"currentVersion":"1.4.0","updatedRecordUrl":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=surmount-1-weight-72w","whatChangedUrl":"https://www.worldpeptidefoundation.org/research/changes","licenseClarification":null,"resultsSha256":"4d6c04b6a80bdeb929e3b9a23214e46aa805359dd916be37817f5e751b5c59a6","license":{"name":"Creative Commons Attribution 4.0 International","identifier":"CC-BY-4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"licenseScope":{"covered":["The stable result identifiers (resultId) and the WPF citation strings","WPF's classification of each study's design (kind)","WPF-written estimand summaries (estimand), the analysis-plan section pointers, and the study-specific limitations (limitations)","The field corrections and their basis notes, and the release changelog","The selection, arrangement and structure of the dataset, and its CSV, BibTeX and JSON renderings","The release metadata and checksum file"],"excluded":["The cited papers and their abstracts, figures and tables (publishers and authors)","ClinicalTrials.gov records, posted results, protocols and statistical analysis plans (linked, not redistributed)","Regulator documents and product labels","Bibliographic identifiers and reported numerical facts as stated by their sources","WPF branding, logos and names","WPF films, transcripts and website copy","WPF repository code"],"unclearAndExcluded":["Fields that closely restate source reports: population, comparator, endpoint, followUp, result, uncertainty, discontinuation, funder and trial names. Ownership of this wording is unresolved, so it is outside the licensed scope until the Owner decides otherwise."]},"suggestedAttribution":"World Peptide Foundation, \"WPF Flagship Weight Management\", version 1.0.0 (2026-11-11), https://www.worldpeptidefoundation.org/releases/wpf-flagship-weight-management/1.0.0/release.json. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Please indicate whether you made changes.","result":{"resultId":"surmount-1-weight-72w","candidateId":"tirzepatide:4","kind":"separate_placebo_controlled","trial":"SURMOUNT-1 (phase 3, double-blind)","agents":"Tirzepatide 5, 10 or 15 mg vs placebo","pmid":"35658024","doi":"10.1056/NEJMoa2206038","registryId":"NCT04184622","population":"2,539 adults with BMI 30 or more, or 27 or more with a weight-related complication, excluding diabetes","comparator":"Placebo (1:1:1:1 randomization), including a 20-week dose-escalation period","endpoint":"Percent change in weight and weight reduction of 5% or more (coprimary)","followUp":"72 weeks","result":"-15.0%, -19.5% and -20.9% with 5, 10 and 15 mg vs -3.1% with placebo","uncertainty":"95% CI -15.9 to -14.2, -20.4 to -18.5, -21.8 to -19.9; placebo -4.3 to -1.9","discontinuation":"Treatment-regimen estimand assessed effects regardless of treatment discontinuation, intention-to-treat population.","funder":"Eli Lilly","registryResultsPosted":true,"registryMasking":"Double","estimand":"Treatment-regimen estimand, regardless of treatment discontinuation, intention-to-treat population (stated in the publication abstract). The public analysis plan has not been reviewed here.","analysisPlan":null,"limitations":["Enrolled adults without diabetes; not evidence for people with type 2 diabetes.","The 72-week period included a 20-week dose escalation, so full-dose exposure was shorter than 72 weeks.","Funded by the manufacturer of tirzepatide."],"citation":"SURMOUNT-1 (phase 3, double-blind). Tirzepatide 5, 10 or 15 mg vs placebo. PMID 35658024; DOI 10.1056/NEJMoa2206038; NCT04184622. World Peptide Foundation, Flagship weight-management comparison, result surmount-1-weight-72w. https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-1-weight-72w","analysisPlanUrl":null,"analysisPlanSections":null,"registryCheckedOn":"2026-11-11","detailUrl":"https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-1-weight-72w"}}